Nasus Pharma Ltd (NSRX)
Score window: May. 30, 2025 to May. 29, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Mar. 11, 2026 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd. has submitted a request to the SEC for the acceleration of the effectiveness of their Registration Statement No. 333-293950. They are seeking to have the stateme… | Read Filing EDGAR |
| Mar. 6, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Nasus Pharma Ltd that they will not review the company's registration statement filed on March 2, 2026. The letter emphasizes that the responsibility f… | Read Filing EDGAR |
| Aug. 8, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd. has submitted a request to the SEC for the acceleration of the effectiveness of its Registration Statement No. 333-288582, aiming for it to become effective on A… | Read Filing EDGAR |
| Aug. 8, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd has submitted a request for the acceleration of the effective date of their Registration Statement on Form F-1, aiming for it to become effective on August 11, 20… | Read Filing EDGAR |
| Aug. 7, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd. has submitted a response to the SEC's comment letter dated August 6, 2025, regarding their Registration Statement on Form F-1. The company has made necessary rev… | Read Filing EDGAR |
| Aug. 6, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed Nasus Pharma Ltd.'s amended registration statement and has issued comments requiring further information and revisions. Key points include the need for disclo… | Read Filing EDGAR |
| Jul. 28, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd. has submitted a response to the SEC's comment letter dated July 16, 2025, regarding their Registration Statement on Form F-1 filed on July 9, 2025. The correspon… | Read Filing EDGAR |
| Jul. 16, 2025 | UPLOAD | Concern from SEC | Moderate | The SEC has reviewed Nasus Pharma Ltd.'s registration statement on Form F-1 and has issued a comment requiring additional information regarding the enantiomeric stability study of… | Read Filing EDGAR |